tuneTypical Dose
2 billion CFU daily, the most commonly studied dose across IBS trials and the standard commercial dose for both BC30 and LactoSpore products
Microbiome Modulator
Bacillus coagulans
Bacillus coagulans
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Some trials show significant separation from placebo within 1-2 weeks. Full assessment of whether B. coagulans is working for you should be made at 8 weeks. If no improvement by 8 weeks, it is reasonable to discontinue.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Bacillus coagulans is a spore-forming probiotic with consistent evidence for reducing abdominal pain, bloating, and diarrhea frequency in adults with IBS, especially IBS-D.
Bacillus coagulans is a spore-forming, lactic acid-producing bacterium with a practical advantage over conventional probiotics. Its dormant spore survives stomach acid and bile without refrigeration, then germinates in the small intestine where it produces L(+)-lactic acid, bacteriocins, and short-chain fatty acids. Multiple small randomized controlled trials and a 2024 meta-analysis of seven RCTs consistently show that B. coagulans reduces abdominal pain, bloating, and stool frequency in IBS patients, with the strongest signal in diarrhea-predominant IBS. The two best-studied commercial strains are GBI-30, 6086 (BC30) and MTCC 5856 (LactoSpore), both at 2 billion CFU daily. Safety is excellent across all published trials. The evidence base is limited by small sample sizes and industry funding, which keeps confidence at C+ rather than higher, but the direction of benefit is consistent and the spore-based delivery advantage is well characterized.
B. coagulans is a spore-forming, lactic acid-producing bacterium. The dormant spore survives gastric acid and bile, then germinates in the small intestine where it produces L(+)-lactic acid, bacteriocins (coagulin), and short-chain fatty acids. It modulates the local gut environment and may shift immune signaling toward increased T-regulatory cell activity and anti-inflammatory cytokine production. It does not permanently colonize and clears after discontinuation.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced abdominal pain severity in adults with IBS
- Reduced bloating severity in adults with IBS
- Reduced daily bowel movement frequency in adults with IBS-D
Secondary Outcomes
- Improved overall IBS symptom severity scores
- Improved bowel habit satisfaction
- Potential contribution to multi-strain antibiotic-associated diarrhea prevention (as part of a blend, not standalone)
Safety
Contraindications and Interactions
Contraindications
- Severe immunocompromise (active chemotherapy, organ transplant on immunosuppressants, advanced HIV)
- Known allergy to B. coagulans or product excipients
Side effects
- Mild gas or bloating
- Transient change in stool consistency
Interactions
- Antibiotics
Avoid if
- Severely immunocompromised without clinician guidance
- Worsening GI symptoms rather than improvement after 2-4 weeks of use
Evidence
Study-level References
bc-SRC-001Randomized, double-blind, placebo-controlled pilot clinical study
Sourceopen_in_newMajeed M, Nagabhushanam K, Natarajan S, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15:21.
Population: Newly diagnosed diarrhea-predominant IBS patients across three clinical centers in India (n=36)
Dose protocol: 2 billion CFU daily of MTCC 5856 (LactoSpore) plus standard care for 90 days in IBS-D patients.
Key findings: Significant reductions in bloating, diarrhea, abdominal pain, and stool frequency versus placebo. No adverse events.
Notes: Small sample (n=36) and industry funding. Concurrent standard care medications complicate clean attribution, but the directional benefit is consistent with other B. coagulans IBS trials.
Paper content
Double-blind, placebo-controlled pilot RCT in 36 newly diagnosed IBS-D patients across three Indian clinical centers. Participants received standard care plus either B. coagulans MTCC 5856 (LactoSpore) at 2 billion CFU/day or placebo for 90 days. The probiotic group showed statistically significant reductions in bloating, diarrhea, abdominal pain, vomiting, and stool frequency compared to placebo. The physician global assessment also favored the active group. No adverse events were reported. The study is limited by its small sample size (n=36), concurrent standard care medications, and single-region recruitment, but it provides direct evidence for B. coagulans MTCC 5856 in IBS-D symptom management.
bc-SRC-002Randomized, double-blind, parallel-group, placebo-controlled clinical trial
Sourceopen_in_newHun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-124.
Population: Adults with irritable bowel syndrome (n=44)
Dose protocol: GBI-30, 6086 once daily for 8 weeks in IBS patients.
Key findings: Statistically significant improvements in abdominal pain and bloating at all weekly comparisons (P < 0.01) in the active group.
Notes: One of the earliest controlled trials for B. coagulans in IBS. Small sample (n=44) and industry funding. No IBS subtyping performed.
Paper content
Randomized, double-blind, placebo-controlled trial evaluating B. coagulans GBI-30, 6086 in 44 adults with IBS. Participants self-assessed abdominal pain and bloating daily for 8 weeks. The active group showed statistically significant improvements in both abdominal pain and bloating at every weekly comparison point (P < 0.01), whereas the placebo group achieved significance only for abdominal pain at weeks 6 and 8. This was one of the earlier well-controlled trials to show a consistent symptom-relief signal for B. coagulans in IBS patients. The trial is limited by its small sample size and lack of IBS subtyping, but it provided early evidence supporting B. coagulans GBI-30, 6086 as a safe, effective option for IBS symptom management.
bc-SRC-003Randomized, double-blind, placebo-controlled pilot clinical trial
Sourceopen_in_newDolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009;31(10):655-659.
Population: Adults with diarrhea-predominant irritable bowel syndrome (IBS-D) (n=52 evaluable from larger enrollment)
Dose protocol: GBI-30, 6086 once daily for 8 weeks in IBS-D patients.
Key findings: Significant reduction in average daily bowel movements (P = 0.042). Severity scores and quality of life not assessable due to baseline variability.
Notes: Small pilot trial. The stool-frequency reduction signal is useful, but the inability to assess severity endpoints limits the trial's contribution.
Paper content
Randomized, double-blind, placebo-controlled pilot trial evaluating GanedenBC30 (B. coagulans GBI-30, 6086) specifically in IBS-D patients over 8 weeks. Among the 52 evaluable IBS-D patients, average daily bowel movements were significantly reduced in the active group compared to placebo (P = 0.042). However, large variability in baseline severity scores prevented clear assessment of symptom severity and quality of life endpoints. This trial is notable as one of the first placebo-controlled studies targeting IBS-D specifically with B. coagulans, confirming safety and providing a stool-frequency reduction signal. Limitations include small sample size and high baseline variability.
bc-SRC-004Randomized, double-blind, placebo-controlled trial
Sourceopen_in_newLeMoire A, Replogle R, Shinn L, Kamil A, Lin L, Kuttenkeuler AP, Baisley J, Wang J, Girard SA, Recker S, Bier A. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. Benef Microbes. 2025;16(5):533-543. doi:10.1163/18762891-bja00072. PMID:40456531.
Population: Healthy adults with infrequent bowel movements (3.0 to less than 7.0 complete spontaneous bowel movements per week).
Dose protocol: B. coagulans Unique IS2 at 2 billion CFU daily for 4 weeks in 144 adults with infrequent bowel movements.
Key findings: Significant improvements in bowel movement frequency (P = 0.037), stool consistency (P = 0.018), and hard stool incidence (P = 0.001) versus placebo.
Notes: Extends the evidence to a non-IBS population with infrequent stools using a third studied strain (Unique IS2). Industry-linked authors.
Paper content
This 4-week placebo-controlled RCT tested Bacillus coagulans Unique IS2 in healthy adults with infrequent bowel movements rather than in patients with IBS or chronic constipation. The intervention improved complete spontaneous bowel-movement frequency, stool consistency, and hard-stool incidence, but it did not clearly improve broader GI symptoms, quality of life, or microbiota composition. That makes it a useful supportive bowel-regularity study, but not a reason to overstate species-wide efficacy beyond the better-established IBS literature.
bc-SRC-005Double-blind, randomized controlled trial
Sourceopen_in_newGang H, Wei J, McFarland LV, Zahra R, Saez ME, Blanco-Rojo R, Millette M. Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial. Benef Microbes. 2025;17(1):29-46. doi:10.1163/18762891-bja00084. PMID:40707016.
Population: Healthy adults aged 18-65 years with functional GI complaints.
Dose protocol: BC30 at 1 billion CFU daily for 4 weeks in 111 healthy adults with functional GI complaints.
Key findings: Significant increases in stool frequency (P = 0.036), improved fecal consistency (P < 0.001), and reduced constipation incidence (P < 0.001) with favorable microbiome shifts.
Notes: Confirms BC30 benefits beyond IBS-specific populations. Conducted in Chinese adults, adding geographic diversity to the evidence base.
Paper content
This RCT tested BC30 at 1 billion CFU daily in 111 healthy Chinese adults with functional GI complaints. After 4 weeks, the probiotic group showed significantly increased weekly stool frequency (P = 0.036), improved fecal consistency (P < 0.001), and reduced constipation incidence (P < 0.001). The microbiota analysis revealed increased Bacteroides and decreased Clostridium, Blautia, and Ruminococcus.